CICC published a report stating that WUXI BIO (02269.HK) -1.600 (-4.828%) Short selling $240.24M; Ratio 17.853% exceeded the firm's expectations for its 2025 results, with revenue reaching RMB21.79 billion, representing a year-on-year growth of 16.7%; net profit was RMB4.91 billion, growing 46.3% year-on-year; and adjusted net profit was RMB5.64 billion, up 17.9% year-on-year.The results surpassed the firm's expectations, with enhanced profitability mainly due to an increased proportion of high-margin businesses, improved capacity utilization, and enhanced operational efficiency. The company guides for a 13-17% year-on-year revenue growth in 2026 (considering exchange rate impacts).Related News UBS Lowers EPS Forecasts for WUXI BIO (02269.HK) for This and Next Year, Slightly Reduces TP to HKD49.3Considering the improvement in operational efficiency, the firm raised WUXI BIO's adjusted net profit for 2026 and 2027 by 6.3% and 9.7%, respectively, to RMB6.21 billion and RMB7.19 billion, maintaining an 'Outperform' rating and raising the target price by 6.7% to HKD48. (ha/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-03-26 16:25.)